298 related articles for article (PubMed ID: 29191584)
1. Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
Aggarwal C; Wang X; Ranganathan A; Torigian D; Troxel A; Evans T; Cohen RB; Vaidya B; Rao C; Connelly M; Vachani A; Langer C; Albelda S
Lung Cancer; 2017 Oct; 112():118-125. PubMed ID: 29191584
[TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
Zhu HH; Liu YT; Feng Y; Zhang LN; Zhang TM; Dong GL; Xing PY; Wang HY; Shi YK; Hu XS
Thorac Cancer; 2021 Oct; 12(20):2749-2757. PubMed ID: 34423906
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer.
Normanno N; Rossi A; Morabito A; Signoriello S; Bevilacqua S; Di Maio M; Costanzo R; De Luca A; Montanino A; Gridelli C; Rocco G; Perrone F; Gallo C
Lung Cancer; 2014 Aug; 85(2):314-9. PubMed ID: 24882383
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of circulating tumor cells in patients with small cell lung cancer.
Naito T; Tanaka F; Ono A; Yoneda K; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Kenmotsu H; Shukuya T; Kaira K; Koh Y; Endo M; Hasegawa S; Yamamoto N
J Thorac Oncol; 2012 Mar; 7(3):512-9. PubMed ID: 22258473
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer.
Cheng Y; Liu XQ; Fan Y; Liu YP; Liu Y; Liu Y; Ma LX; Liu XH; Li H; Bao HZ; Liu JJ; Zhang S; Wu CJ
Future Oncol; 2016 Mar; 12(6):789-99. PubMed ID: 26838372
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.
Hiltermann TJN; Pore MM; van den Berg A; Timens W; Boezen HM; Liesker JJW; Schouwink JH; Wijnands WJA; Kerner GSMA; Kruyt FAE; Tissing H; Tibbe AGJ; Terstappen LWMM; Groen HJM
Ann Oncol; 2012 Nov; 23(11):2937-2942. PubMed ID: 22689177
[TBL] [Abstract][Full Text] [Related]
9. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
Belani CP; Dahlberg SE; Rudin CM; Fleisher M; Chen HX; Takebe N; Velasco MR; Tester WJ; Sturtz K; Hann CL; Shanks JC; Monga M; Ramalingam SS; Schiller JH
Cancer; 2016 Aug; 122(15):2371-8. PubMed ID: 27163943
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
Tay RY; Fernández-Gutiérrez F; Foy V; Burns K; Pierce J; Morris K; Priest L; Tugwood J; Ashcroft L; Lindsay CR; Faivre-Finn C; Dive C; Blackhall F
Ann Oncol; 2019 Jul; 30(7):1114-1120. PubMed ID: 31020334
[TBL] [Abstract][Full Text] [Related]
11. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
12. TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).
Messaritakis I; Stoltidis D; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Politaki E; Apostolaki S; Souglakos J; Georgoulias V
Sci Rep; 2017 Mar; 7():45351. PubMed ID: 28349943
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis.
Jiang AM; Zheng HR; Liu N; Zhao R; Ma YY; Bai SH; Tian T; Liang X; Ruan ZP; Fu X; Yao Y
Cancer Control; 2021; 28():10732748211050581. PubMed ID: 34654345
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
Hou JM; Krebs MG; Lancashire L; Sloane R; Backen A; Swain RK; Priest LJ; Greystoke A; Zhou C; Morris K; Ward T; Blackhall FH; Dive C
J Clin Oncol; 2012 Feb; 30(5):525-32. PubMed ID: 22253462
[TBL] [Abstract][Full Text] [Related]
15. Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib.
Messaritakis I; Politaki E; Koinis F; Stoltidis D; Apostolaki S; Plataki M; Dermitzaki EK; Georgoulias V; Kotsakis A
Sci Rep; 2018 Feb; 8(1):2238. PubMed ID: 29396560
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
[TBL] [Abstract][Full Text] [Related]
17. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.
Juan O; Vidal J; Gisbert R; Muñoz J; Maciá S; Gómez-Codina J
Clin Transl Oncol; 2014 Jul; 16(7):637-43. PubMed ID: 24217975
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of circulating tumor cells in patients with small-cell lung cancer.
Wang YL; Liu CH; Li J; Ma XP; Gong P
Tumori; 2017 May; 103(3):242-248. PubMed ID: 28218384
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
Hou JM; Greystoke A; Lancashire L; Cummings J; Ward T; Board R; Amir E; Hughes S; Krebs M; Hughes A; Ranson M; Lorigan P; Dive C; Blackhall FH
Am J Pathol; 2009 Aug; 175(2):808-16. PubMed ID: 19628770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
